Summary:
Protocol Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
Qualified Participants Must:
• Be 18 to 65 years old
•
Have a BMI between 30 and 40
•
Be generally healthy (not taking any medication)
•
Be avaliable for 3 SEPERATE 3-day/2-night stays at the research center and approximately 19 outpatient visits
•
Women must have their falopian tubes removed OR have ovaries removed OR have a hysterectomy OR be post menopausal